摘要:
Compounds of the following backbone structure: which are useful as Tumor necrosis factor (TNF) inhibitors in treating disease related to elevated TNF.
摘要:
Compounds of formula (I) are described in which R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 is a group —L1—R7 or —L2—R8 [where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, —S(O)nR9, —NHSO2R9, —C(═Z)OR10, —C(═Z)R10, —OR10, —N(R11)—C(═Z)R9, —NY1Y2, —SO2NY1Y2, —C(═Z)—NY1Y2, —N(R11)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)R10, —C(═NOR10)R10, —C(═Z)NR10OR12, —N(R11)—C(═NR13)—NY1Y2 or —N(R11)—C(═Z)OR11; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalkyl]; R4 is a group —L3—R14 [where L3 is a direct bond or an optionally substituted alkylene linkage and R14 is hydrogen, alkyl, azido, hydroxy, alkoxy, aryl, arylalkyloxy, aryloxy, carboxy (or an acid bioisostere), cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, heterocycloalkyl, heterocycloalkyloxy, nitro, —NY4Y5, —N(R10)—C(═Z)—R15; —N(R10)—C(═Z)—L4—R16, —NH—C(═Z)—NH—R15, —NH—C(═Z)—NH—L4—R16, —N(R10)—SO2—R15, —N(R10)—SO2—L4—R16, —S(O)nR9, —C(═Z)—NY4Y5 or —C(═Z)—OR9]; R5 is hydrogen, alkyl or hydroxyalkyl; or R4 and R5, when attached to the same carbon atom, may form with the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring or a group C═CH2; R6 is hydrogen or alkyl; and m is zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of compounds of formula (I) and N-oxides thereof, and their prodrugs. The compounds are TNF inhibitors and are useful as pharmaceuticals.
摘要翻译:描述式(I)的化合物,其中R 1是任选取代的杂芳基; R2是任选取代的芳基或任选取代的杂芳基; R3是基团-L1-R7或-L2-R8 [其中L1是任选取代的亚烷基键; R 7是氢,芳基,氰基,环烷基,杂芳基,杂环烷基,硝基,-S(O)n R 9,-NHSO 2 R 9,-C(= Z)OR 10,-C(= Z)R 10,-OR 10,-N(R 11) -C(= Z)R9,-NY1Y2,-SO2NY1Y2,-C(= Z)-NY1Y2,-N(R11)-C(= Z)-NY1Y2,-N(OR10)-C(= Z)-NY1Y2 ,-N(OR 10)-C(= Z)R 10,-C(= NOR 10)R 10,-C(= Z)NR 10 OR 12,-N(R 11)-C(= NR 13)-NY 1 Y 2或-N(R 11) C(= Z)OR 11; L2是直接键或包含2至约6个碳原子并含有双或三碳 - 碳键的直链或支链碳链; 和R8是氢,芳基,环烯基,环烷基,杂芳基或杂环烷基]; R4是基团-L3-R14 [其中L3是直接键或任选取代的亚烷基键,R 14是氢,烷基,叠氮基,羟基,烷氧基,芳基,芳基烷氧基,芳氧基,羧基(或酸式生物电子等排体) 杂芳基烷氧基,杂芳氧基,杂环烷基,杂环烷氧基,硝基,-NY 4 Y 5,-N(R 10)-C(= Z)-R 15; -N(R10)-C(= Z)-L4-R
摘要:
Therapeutically useful isoquinolinone derivatives of the formula A--X--R.sup.3, wherein A represents a group of the formula: ##STR1## wherein R.sup.1 and R.sup.2 represents cycloalkyl, alkyl, alkenyl or alkynyl optionally substituted by halogen or cycloalkyl, or represents optionally substituted aryl or heteroaryl, R.sup.4 represents hydrogen, halogen, optionally substituted alkyl, alkenyl or alkynyl, optionally substituted aryl or heteroaryl, or a group R.sup.6 O-- wherein R.sup.6 represents alkyl, aryl or arylalkyl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula:--Y.sup.1 --CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5wherein Y.sup.1 represents carbonyl, hydroxymethylene or --C(OR).sub.2 -- wherein R represents alkyl or the two R symbols together represent alkylene and R.sup.5 represents hydrogen or optionally substituted alkyl or R.sup.3 represents a lactol or lactone ring, and pharmaceutically acceptable salts thereof, processes for their preparation and compositions containing them are described.
摘要:
Therapeutically useful pyrrolo[2,1-a]phthalazine derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 represent cycloalkyl, optionally substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula:--Y--CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5wherein Y represents carbonyl or hydroxymethylene and R.sup.5 represents hydrogen or optionally substituted alkyl, or R.sup.3 represents a lactone ring and the symbols R.sup.4 represent hydrogen, halogen, optionally substituted alkyl, alkenyl, alkynyl, aryl or heteroaryl, or R.sup.6 O-- wherein R.sup.6 represents alkyl, aryl or arylalkyl and salts thereof, processes for their preparation and compositions containing them are described.
摘要:
Pyrrolo[2,1-a]isoquinoline derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2 each represent cycloalkyl or alkyl, alkenyl or alkynyl which may be halogen-substituted, or optionally substituted aryl or heteroaryl, X represents ethylene or vinylene, R.sup.3 represents a group of the formula:--Y--CH.sub.2 --CH(OH)--CH.sub.2 --COOR.sup.5 IIwherein Y represents carbonyl or hydroxymethylene and R.sup.5 represents hydrogen or optionally substituted alkyl, or R.sup.3 represents a lactone ring, and the symbols R.sup.4 represent hydrogen, halogen, optionally substituted alkyl, alkenyl or alkynyl, optionally substituted aryl or heteroaryl, or a group of the formula R.sup.6 O--, wherein R.sup.6 represents alkyl, aryl or arylalkyl and pharmaceutical properties.
摘要:
Ethene derivatives of the formula:[R.sup.5 (R.sup.1 CR.sup.4 .dbd.CR.sup.2 R.sup.3).sub.m ].sub.n Iwherein R.sup.5 represents optionally substituted heterocyclyl or a group --CR.sup.4 .dbd.CR.sup.2 R.sup.3, or optionally substituted aryl, heterocyclylalkyl or arylalkyl and R.sup.1 represents --NR.sup.6 -- wherein R.sup.6 represents hydrogen or optionally substituted alkyl or aryl, or R.sup.5 represents a quinonoidal group, and R.sup.1 represents .dbd.N--, R.sup.4 represents hydrogen, alkoxy, alkylthio, trifluoromethyl or optionally substituted alkyl or aryl, R.sup.2 represents cyano, formyl, alkoxycarbonyl, alkylsulphonyl, dialkylcarbamoyl, dialkylthiocarbamoyl, aryloxycarbonyl, arylsulphinyl or arylsulphonyl, R.sup.3 represents a group R.sup.2 or hydrogen, nitro or optionally substituted aryl or aroyl or alkanoyl, and m and n are 1 or 2, and pharmaceutically acceptable salts thereof, with the exclusion of certain compounds in which R.sup.5 represents pyridyl, 5-halogenopyrid-2-yl or 1,2,4-triazolo[4,3-a]-quinoline possess useful pharmacological properties.